Mizuho analyst Graig Suvannavejh lowered the firm’s price target on Athira Pharma (ATHA) to $4 from $5 and keeps a Neutral rating on the shares following the 10-for-1 reverse stock split. The split has no impact on the company’s underlying fundamentals, the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATHA:
- Athira Pharma trading halted, news pending
- Upcoming Stock Splits This Week (September 15 to September 19) – Stay Invested
- Athira Pharma Announces 10-for-1 Reverse Stock Split
- Athira Pharma announces a 10-for-1 reverse stock split
- Athira Pharma presents results from Phase 1 trial of ATH-1105 at ALS Nexus